Table 1 Summary of examined studies.

Battipaglia et al. 2017¹⁴

Retrospective; HCT in 146 adults

4 patients

2 developed VOD/SOS

VOD/SOS treated with DF in 2 patients; both survived (1 received prophylaxis with DF, the other received heparin)

Richardson et al. 2010¹⁵

20 adult and pediatric patients with VOD/SOS and MOD

—

—

All received DF (phase 2 dose-finding study); Day 100 survival was 50% (n = 10/20); trend toward higher CR rate in GO subgroup

Zwaan et al. 2010¹⁶

30 pediatric patients treated for AML relapse

8 patients

No cases of VOD/SOS

—

Bornhäuser et al. 2008¹⁷

31 patients with refractory AML

—

—

1 case of VOD/SOS after HCT; treated successfully with DF

Lannoy et al. 2006¹⁸

1 patient treated for relapsed AML

—

—

DF deemed effective in treating symptoms of VOD/SOS; death attributed to GO failure

Reinhardt et al. 2004¹⁹

12 pediatric patients treated for relapsed AML

—

—

1 patient with VOD/SOS treated successfully with DF

Versluys et al. 2004²⁰

7 patients treated for relapsed AML prior to HCT

6 patients

No cases of VOD/SOS

1 patient without DF prophylaxis had severe VOD/SOS, which was successfully treated with DF

Saviola et al. 2003²¹

1 adult with refractory AML

—

—

VOD/SOS treated successfully with DF

Corbacioglu et al. 2015^22a

16 pediatric patients at high risk of VOD/SOS prior to HCT

11 patients

2 developed VOD/SOS

—